Role of Inflammation and Motility Disorders in the Development, Course and Consequences of Functional Gastrointestinal and Biliary Tract Diseases (Literature Review and Expert Panel Resolution)

   Aim: to present the results of the Expert Panel with a discussion of modern concepts of the pathogenesis of functional gastrointestinal diseases and the possibilities of multitarget therapy with trimebutine.

   Key points. Low-grade inflammation can be considered as a morphological substrate of functional diseases with an increase in activated mastocytes and eosinophils, T-helpers 2 and T-helpers 17 in the gastrointestinal mucosa. In the development in the content of visceral hypersensitivity, the functional connection between mastocytes and TRPV1-positive sensory endings of the vagus nerve is of great importance. Proinflammatory cytokines and matrix metalloproteinases can enter the systemic circulation, provoking the development of systemic manifestations. Increased levels of proinflammatory cytokines are supported by altered intestinal permeability and microbiota. Functional diseases are believed to modify the symptoms and course of concomitant organic diseases of the gastrointestinal tract (for example, functional diseases of the biliary tract may contribute to the development of cholelithiasis, pancreatitis). The peripheral μ-, κ- and δ-receptor agonist trimebutine (Trimedat®) regulates the production of enterohormones, modulates motility throughout the gastrointestinal tract and normalizes visceral sensitivity. The effectiveness of trimebutine in the treatment of functional disorders has been shown in various studies. Trimebutine helps reduce the production of proinflammatory cytokines, including interleukin-6.

   Conclusion. In the treatment of functional diseases of the gastrointestinal tract, trimebutine can be considered as a multitarget agent, since the drug helps to normalize motility, reduces the degree of visceral hypersensitivity, exhibits anti-inflammatory and neuroregenerative effects, and can also increase the effectiveness of treatment of concomitant diseases.

1. Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. DOI: 10.1053/j.gastro.2020.04.014

2. Silaeva A.S., Bueverova E.L., Shulpekova Yu.O. Duodenal eosinophilia in functional dyspepsia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(2):87–94. (In Russ.) DOI: 10.22416/1382-4376-2023-33-2-87-94

3. Burns G., Carroll G., Mathe A., Horvat J., Foster P., Walker M.M., et al. Evidence for local and systemic immune activation in functional dyspepsia and the irritable bowel syndrome : A systematic review. Am J Gastroenterol. 2019;114(3):429–36. DOI: 10.1038/s41395-018-0377-0

4. Wouters M.M., Vicario M., Santos J. The role of mast cells in functional GI disorders. Gut. 2016;65(1):155–68. DOI: 10.1136/gutjnl-2015-309151

5. Burns G.L., Bruce J.K., Minahan K., Mathe A., Fairlie T., Cameron R., et al. Type 2 and type 17 effector cells are increased in the duodenal mucosa but not peripheral blood of patients with functional dyspepsia. Front Immunol. 2023:13:1051632. DOI: 10.3389/fimmu.2022.1051632

6. Arshi J., Layfield L.J., Esebua M. Mast cell infiltration and activation in the gallbladder wall: Implications for the pathogenesis of functional gallbladder disorder in adult patients. Ann Diagn Pathol. 2021;54:151798. DOI: 10.1016/j.anndiagpath.2021.151798

7. Oshima T. Functional dyspepsia: Current understanding and future perspective. Digestion. 2024;105(1):26–33. DOI: 10.1159/000532082

8. Defaye M., Abdullah N.S., Iftinca M., Hassan A., Agosti F., Zhang Z., et al. Gut-innervating TRPV1+ neurons drive chronic visceral pain via microglial P2Y12 receptor. Cell Mol Gastroenterol Hepatol. 2022;13(4):977–99. DOI: 10.1016/j.jcmgh.2021.12.012

9. Seyedmirzaee S., Hayatbakhsh M.M., Ahmadi B., Baniasadi N., Bagheri Rafsanjani A.M., Nikpoor A.R., et al. Serum immune biomarkers in irritable bowel syndrome. Clin Res Hepatol Gastroenterol. 2016;40(5):631–7. DOI: 10.1016/j.clinre.2015.12.013

10. Mokhtare M., Alimoradzadeh R., Agah S., Mirmiranpour H., Khodabandehloo N. The association between modulating inflammatory cytokines and constipation of geriatrics in Iran. Middle East J Dig Dis. 2017;9(4):228–34. DOI: 10.15171/mejdd.2017.78

11. Kumar S., Singh P., Kumar A. Targeted therapy of irritable bowel syndrome with anti-inflammatory cytokines. Clin J Gastroenterol. 2022;15(1):1–10. DOI: 10.1007/s12328-021-01555-8

12. Norlin A.K., Walter S., Icenhour A., Keita A.V., Elsenbruch S., Bednarska O., et al. Fatigue in irritable bowel syndrome is associated with plasma levels of TNF-alpha and mesocorticolimbic connectivity. Brain Behav Immun. 2021;92:211–22. DOI: 10.1016/j.bbi.2020.11.035

13. Šojat D., Volarić M., Keškić T., Volarić N., Cerovečki V., Trtica Majnarić L. Putting functional gastrointestinal disorders within the spectrum of inflammatory disorders can improve classification and diagnostics of these disorders. Biomedicines. 2024;12(3):702. DOI: 10.3390/biomedicines12030702

14. Wei L., Singh R., Ro S., Ghoshal U.C. Gut microbiota dysbiosis in functional gastrointestinal disorders: Underpinning the symptoms and pathophysiology. JGH Open. 2021;5(9):976–87. DOI: 10.1002/jgh3.12528

15. Mekhdiyev S.N., Mekhdieva O.A., Berko O.M. Overlap of functional gastrointestinal disorders: Common mechanisms of pathogenesis as a key to rational therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):95–103. (In Russ.) DOI: 10.22416/1382-4376-2022-32-4-95-103

16. Lee S.W., Chang C.S. Impact of overlapping functional gastrointestinal disorders on the quality of life in patients with gastroesophageal reflux disease. J Neurogastroenterol Motil. 2021;27(2):176–84. DOI: 10.5056/jnm19006

17. Simon D.A., Friesen C.A., Schurman J.V., Colombo J.M. Biliary dyskinesia in children and adolescents : A mini review. Front Pediatr. 2020;8:122. DOI: 10.3389/fped.2020.00122

18. Ivashkin V.T., Mayev I.V., Shulpekova Yu.O., Baranskaya Ye.K., Okhlobystin A.V., Trukhmanov A.S., et al. Diagnostics and treatment of biliary dyskinesia: Clinical guidelines of the Russian gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(3):63–80. (In Russ.) DOI: 10.22416/1382-4376-2018-28-3-63-80

19. Kutcheryavy Yu.A. Pain and dyspepsia following cholecystectomy. Doctor.Ru. Gastroenterology. 2016;118(1):27–32. (In Russ.)

20. Ilchenko A.A. Biliary pancreatitis. Russian Medical Journal. 2012;20(15):803. (In Russ.)

21. Cotton P.B., Elta G.H., Carter C.R., Pasricha P.J., Corazziari E.S. Rome IV. Gallbladder and sphincter of Oddi disorders. Gastroenterology. 2016:S0016-5085(16)00224-9. DOI: 10.1053/j.gastro.2016.02.033

22. Futagami S., Wakabayashi M. Pancreatic dysfunction and duodenal inflammatory responses coordinate with refractory epigastric pain including functional dyspepsia : A narrative review. J Nippon Med Sch. 2022;89(3):255–62. DOI: 10.1272/jnms.JNMS.2022_89-311

23. Zanchi C., Pintaldi S., Di Leo G., Ronfani L., Zamagni G., Viel M., et al. Fifteen-years follow-up in a cohort of children with functional gastrointestinal disorders: Prevalence and risk factors to develop neuropsychiatric disorders and other comorbidities. Children (Basel). 2021;8(10):838. DOI: 10.3390/children8100838

24. Delvaux M., Wingate D. Trimebutine: Mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225–46. DOI: 10.1177/030006059702500501

25. Ruepert L., Quartero A.O., de Wit N.J., van der Heijden G.J., Rubin G., Muris J.W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011(8):CD003460. DOI: 10.1002/14651858. CD003460.pub3

26. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355–61. DOI: 10.1046/j.1365-2036.2001.00937.x

27. Ivashkin V.T., Poluektova Ye.A., Reykhart D.V., Shifrin O.S., Beniashvili A.G., Lyashenko O.S., et al. Efficacy of drugs most commonly prescribed at functional gastrointestinal diseases (functional dyspepsia syndrome and irritable bowel syndrome) observational study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):14–23. (In Russ.) DOI: 10.22416/1382-4376-2016-4-14-23

28. Rahman M.Z., Ahmed D.S., Mahmuduzzaman M., Rahman M.A., Chowdhury M.S., Barua R., et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014;23(1):105–13.

29. Kardasheva S.S., Kartavenko I.M., Maksimova N.B., Yurieva E.Yu., Popova I.R., Pavlov Ch.S., et al. Efficacy of trime-butine maleate (Trimedat®) in the treatment of patients with functional dyspepsia: Results of the “TREND” observational study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(5):67–76. (In Russ.) DOI: 10.22416/1382-4376-2018-28-5-67-76

30. Kountouras J., Gavalas E., Papaefthymiou A., Tsechelidis I., Polyzos S.A., Bor S., et al. Trimebutine maleate monotherapy for functional dyspepsia: A multicenter, randomized, double-blind placebo controlled prospective trial. Medicina (Kaunas). 2020;56(7):339. DOI: 10.3390/medicina56070339

31. Yang Y.J., Bang C.S., Baik G.H., Park T.Y., Shin S.P., Suk K.T., et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017;17(1):83. DOI: 10.1186/s12876-017-0639-0

32. Svistunov A.A., Butorova L.I., Osadchuk M.A., Kireeva N.V., Tokmulina G.M., Ardatskaya M.D. The biliary pain syndrome in the context of Rome IV criteria: the rational approach to the choice of spasmolytic therapy in the clinical practice. Russian Journal of Evidence-Based Gastroenterology. 2018;7(2):59–69. (In Russ.) DOI: 10.17116/dokgastro20187259

33. Ivashkin V.T., Pavlov C.S., Popova I.R., Shulpekova Yu.O. Trimebutine maleate in the treatment of functional biliary disorders: Tribune study results. Meditsinskiy sovet = Medical Council. 2018;21:117–25. (In Russ.) DOI: 10.21518/2079-701X-2018-21-117-125

34. Yakovenko E.P., Agafonova N.A., Yakovenko A.V., Ivanov A.N., Kagramanova A.V. Оpioid receptors agonist Trimebutine in treatment of functional gallbladder and Oddy's sphincter disorders. Lechaschi Vrach. 2014;2:56–60. (In Russ.)

35. Vitton V., Delpy R., Gasmi M., Lesavre N., Abou-Berdugo E., Desjeux A., et al. Is endoscopic sphincterotomy avoidable in patients with sphincter of Oddi dysfunction? Eur J Gastroenterol Hepatol. 2008;20(1):15–21. DOI: 10.1097/MEG.0b013e3282eeb4a1

36. Andreev D.N., Maev I.V. Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study. Terapevticheskii Arkhiv. 2021;93(8):897–903. (In Russ.) DOI: 10.26442/00403660.2021.08.200919

37. Ogawa N., Nakajima S., Tamada K., Yokoue N., Tachibana H., Okazawa M., et al. Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages. Arch Biochem Biophys. 2021;711:109029. DOI: 10.1016/j.abb.2021.109029

38. Kornienko E.A., Tipikina M.Yu., Kubalova S.S., Karpinchuk D.N., Parolova N.I. New aspects of the mechanisms of development and treatment of irritable bowel syndrome. Voprosy Prakticheskoi Pediatrii. 2011;6(5):8–14. (In Russ.)

39. Gao M., Zuou H., Zhu Y., Chen Y. Effect of trimebutine maleate tablets on serum TNF-α, IL-23, ESR, D-D ulcerative colitis in patients with ulcerative colitis. Chinese Journal of Biochemical Pharmaceutics. 2017;6:204–6.

40. Xu J., Hu C., Jiang Q., Pan H., Shen H., Schachner M. Trimebutine, a small molecule mimetic agonist of adhesion molecule L1, contributes to functional recovery after spinal cord injury in mice. Dis Model Mech. 2017;10(9):1117–28. DOI: 10.1242/dmm.029801

41. Salvioli B. Trimebutine : A state-of-the-art review. Minerva Gastroenterol Dietol. 2019;65(3):229–38. DOI: 10.23736/S1121-421X.19.02567-4

42. Trukhan D.I., Grishechkina I.A., Bykhovtsev N.A. Trimebutin in the treatment of irritable bowel syndrome and other functional gastrointestinal disorders. Meditsinskiy sovet = Medical Council. 2016;19:82–6. (In Russ.) DOI: 10.21518/2079-701X-2016-19-82-86

43. Kountouras J., Chatzopoulos D., Zavos C., Boura P., Venizelos J., Kalis A. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002;49(43):193–7.

44. Nogi K., Haruma K., Taniguchi H., Yomota E., Okajima M., Hananoki M., et al. Duodenogastric reflux following cholecystectomy in the dog: Role of antroduodenal motor function. Aliment Pharmacol Ther. 2001;15(8):1233–8. DOI: 10.1046/j.1365-2036.2001.01035.x